Companies › Exegenesis Bio
1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Feb 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EXG102-031 Blocks abnormal blood vessel formation and leakage | – | Phase 1 | Neovascular Age-Related Macular Degeneration (nAMD) | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06817343 | EXG102-031 | Phase 1 | Neovascular Age-Related Macular Degeneration (nAMD) | Ophthalmology | Feb 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.